Chalcone: A new scaffold for the development of anti-epileptic medications
Abstract
Flavonoids chalcones are a highly attended subclass of flavonoids having structural features and a β-unsaturated carbonyl system which have been identified to have the C band in the purine binding region and are promising molecules in the synthesis of new AEDs. Seizure disorder which presents as epilepsy – an episode of neurological dysfunction described by recurrent seizures – is still a major public health issue, especially in LMICs due to inadequate access to antiseizure medication. Even with the newly developed anti-seizure drugs and novel surgical approaches, nearly 30% of patients continue to be pharmacological treatment resistant thus the development of new pharmacological therapies. This review discusses the structural flexibility and pharmacological application of chalcones to overcome the drawbacks associated with first-generation AEDs. Exploring the possibility of altering chalcones’ Functional Selectivity Profile for GABA receptors, as well as imp/map targets along with sodium and calcium channels could potentially lead to the development of a rational therapeutic strategy for drug-resistant epilepsy. Some investigators have also shown that certain chalcone derivatives have substantial anticonvulsant effects, better therapeutic profiles, and lesser harmful effects than standard AEDs. The superior formation of chalcones through microwave-assisted and green chemistry also supports the various strategies for fouling chalcones with improved therapeutic promise and bioavailability. It also provides information regarding the ability of chalcones as multi-target directed drugs, structure-activity relationships, and some issues related to the regulation of chalcones for clinical use. Despite being switchable phase II enzymes that possess diverse multi-parametric action potentials, chalcones present the possibility to design advanced AED drugs. Further discovery of pharmacodynamics, safety profiles, and factors determining the efficiency of such chalcones will remain the key to enhancing the probability of chalcones becoming effective epilepsy treatments.
References
Aksöz, Begüm Evranos, and Rahmiye Ertan. 2011. “Chemical and Structural Properties of Chalcones I.” J. Pharm. Sci. Vol. 36.
Alka N. Choudhary, Arun Kumar, and Vijay Juy. 2012. “Design, Synthesis and Evaluation of Chalcone Derivatives as Anti- Inflammatory, Antioxidant and Antiulcer Agents.” Letters in Drug Design & Discovery 9 (5): 479–88. https://doi.org/10.2174/157018012800389368.
Ávila, Hugo Pereira, Elza de Fátima Albino Smânia, Franco Delle Monache, and Artur Smânia. 2008. “Structure-Activity Relationship of Antibacterial Chalcones.” Bioorganic & Medicinal Chemistry (Print) 16 (22): 9790–94. https://doi.org/10.1016/j.bmc.2008.09.064.
Benarroch, Eduardo. 2021. “What Is the Role of GABA Transporters in Seizures?” Neurology 97 (12): 580–84. https://doi.org/10.1212/WNL.0000000000012574.
Cancino, Karina, Inés Castro, Carlos Yauri, Valérie Jullian, Jorge Arévalo, Michel Sauvain, Vanessa Adaui, and Denis Castillo. 2021. “Toxicity Assessment of Synthetic Chalcones with Antileishmanial Potential in BALB/c Mice.” Revista Peruana de Medicina Experimental y Salud Pública 38 (3): 424–33. https://doi.org/10.17843/RPMESP.2021.383.6937.
Catterall, William A. 2014. “Sodium Channels, Inherited Epilepsy, and Antiepileptic Drugs.” Annual Review of Pharmacology and Toxicology 54:317–38. https://doi.org/10.1146/ANNUREV-PHARMTOX-011112-140232.
Depondt, Chantal. 2006. “The Potential of Pharmacogenetics in the Treatment of Epilepsy.” European Journal of Paediatric Neurology 10 (2): 57–65. https://doi.org/10.1016/j.ejpn.2005.11.009.
Dhaliwal, Jagjit Singh, Said Moshawih, Khang Wen Goh, Mei Jun Loy, Md Sanower Hossain, Andi Hermansyah, Vijay Kotra, et al. 2022a. “Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives.” Molecules 2022, Vol. 27, Page 7062 27 (20): 7062. https://doi.org/10.3390/MOLECULES27207062.
Donaire-Arias, Ana, Martin L. Poulsen, Jaime Ramón-Costa, Ana Maria Montagut, Roger Estrada-Tejedor, and José I. Borrell. 2023. “Synthesis of Chalcones: An Improved High-Yield and Substituent-Independent Protocol for an Old Structure.” Molecules 28 (22): 7576. https://doi.org/10.3390/MOLECULES28227576.
Elkanzi, Nadia A.A., Hajer Hrichi, Ruba A. Alolayan, Wassila Derafa, Fatin M. Zahou, and Rania B. Bakr. 2022. “Synthesis of Chalcones Derivatives and Their Biological Activities: A Review.” ACS Omega 7 (32): 27769. https://doi.org/10.1021/ACSOMEGA.2C01779.
Fritschy, Jean Marc. 2008. “Epilepsy, E/I Balance and GABAA Receptor Plasticity.” Frontiers in Molecular Neuroscience 1 (MAR): 201. https://doi.org/10.3389/NEURO.02.005.2008/BIBTEX.
Gaonkar, Santosh L., and U. N. Vignesh. 2017. “Synthesis and Pharmacological Properties of Chalcones: A Review.” Research on Chemical Intermediates 43 (11): 6043–77. https://doi.org/10.1007/S11164-017-2977-5.
George, Ginson, Vishal Payyalot Koyiparambath, Sunitha Sukumaran, Aathira Sujathan Nair, Leena K. Pappachan, Abdullah G. Al-Sehemi, Hoon Kim, and Bijo Mathew. 2022. “Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors.” International Journal of Molecular Sciences 23 (6): 3121. https://doi.org/10.3390/IJMS23063121.
Go, M., X. Wu, and X. Liu. 2005. “Chalcones: An Update on Cytotoxic and Chemoprotective Properties.” Current Medicinal Chemistry 12 (4): 483–99. https://doi.org/10.2174/0929867053363153.
Gomes, Marcelo N., Eugene N. Muratov, Maristela Pereira, Josana C. Peixoto, Lucimar P. Rosseto, Pedro V.L. Cravo, Carolina H. Andrade, and Bruno J. Neves. 2017. “Chalcone Derivatives: Promising Starting Points for Drug Design.” Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry 22 (8): 1210. https://doi.org/10.3390/MOLECULES22081210.
Issaoui, Ahmad, and Ferhat Koçak. 2023. “The Treatment of Epilepsy.” Actualites Pharmaceutiques 62 (627): 39–44. https://doi.org/10.1016/j.actpha.2023.03.047.
Liu, Wenjing, Min He, Yongjun Li, Zhiyun Peng, and Guangcheng Wang. 2022. “A Review on Synthetic Chalcone Derivatives as Tubulin Polymerisation Inhibitors.” Journal of Enzyme Inhibition and Medicinal Chemistry 37 (1): 9–38. https://doi.org/10.1080/14756366.2021.1976772.
Lu, Xi, Yong Yang, Ruijiao Zhou, Yun Li, Yi Yang, and Xuefeng Wang. 2019. “Protrudin Modulates Seizure Activity through GABAA Receptor Regulation.” Cell Death & Disease 2019 10:12 10 (12): 1–13. https://doi.org/10.1038/s41419-019-2118-8.
Mahapatra, Debarshi Kar, Sanjay Kumar Bharti, and Vivek Asati. 2017. “Chalcone Derivatives: Anti-Inflammatory Potential and Molecular Targets Perspectives.” Current Topics in Medicinal Chemistry 17 (28): 3146–69. https://doi.org/10.2174/1568026617666170914160446.
Mallia, Ajay, and Joseph Sloop. 2023. “Advances in the Synthesis of Heteroaromatic Hybrid Chalcones.” Molecules 2023, Vol. 28, Page 3201 28 (7): 3201. https://doi.org/10.3390/MOLECULES28073201.
Maronpot, Robert R. 2015. “Toxicological Assessment of Ashitaba Chalcone.” Food and Chemical Toxicology 77 (March):111–19. https://doi.org/10.1016/J.FCT.2014.12.021.
Marotta, Ludovica, Sara Rossi, Roberta Ibba, Simone Brogi, Vincenzo Calderone, Stefania Butini, Giuseppe Campiani, and Sandra Gemma. 2022a. “The Green Chemistry of Chalcones: Valuable Sources of Privileged Core Structures for Drug Discovery.” Frontiers in Chemistry 10 (September):988376. https://doi.org/10.3389/FCHEM.2022.988376/BIBTEX.
Meldrum, Brian S. 1996. “Update on the Mechanism of Action of Antiepileptic Drugs.” Epilepsia 37 Suppl 6 (SUPPL. 6). https://doi.org/10.1111/J.1528-1157.1996.TB06038.X.
Mezgebe, Kibrom, Yadessa Melaku, and Endale Mulugeta. 2023a. “Synthesis and Pharmacological Activities of Chalcone and Its Derivatives Bearing N-Heterocyclic Scaffolds: A Review.” ACS Omega. American Chemical Society. https://doi.org/10.1021/acsomega.3c01035.
Mohamed, Mamdouh F.A., and Gamal El Din A. Abuo-Rahma. 2020. “Molecular Targets and Anticancer Activity of Quinoline–Chalcone Hybrids: Literature Review.” RSC Advances 10 (52): 31139–55. https://doi.org/10.1039/D0RA05594H.
Moreira, Joana, Joana Almeida, Lucília Saraiva, Honorina Cidade, and Madalena Pinto. 2021. “Chalcones as Promising Antitumor Agents by Targeting the P53 Pathway: An Overview and New Insights in Drug-Likeness.” Molecules 2021, Vol. 26, Page 3737 26 (12): 3737. https://doi.org/10.3390/MOLECULES26123737.
Okolo, Emelda N., David I. Ugwu, Benjamin E. Ezema, Joseph C. Ndefo, Florence U. Eze, Chidimma G. Ezema, James A. Ezugwu, and Oguejiofo T. Ujam. 2021. “New Chalcone Derivatives as Potential Antimicrobial and Antioxidant Agent.” Scientific Reports 2021 11:1 11 (1): 1–13. https://doi.org/10.1038/s41598-021-01292-5.
Olsen, Richard W., and Werner Sieghart. 2009. “GABA A Receptors: Subtypes Provide Diversity of Function and Pharmacology.” Neuropharmacology 56 (1): 141–48. https://doi.org/10.1016/J.NEUROPHARM.2008.07.045.
Ouyang, Yang, Juanjuan Li, Xinyue Chen, Xiaoyu Fu, Si Sun, and Qi Wu. 2021. “Chalcone Derivatives: Role in Anticancer Therapy.” Biomolecules 2021, Vol. 11, Page 894 11 (6): 894. https://doi.org/10.3390/BIOM11060894.
Paul, Rahit, Saikat Sen, Debalina Adak, Ankita Porey, and Shaileyee Das. 2023. “A Review: Green Synthesis of Chalcone.” Tuijin Jishu/Journal of Propulsion Technology. Vol. 44.
Perucca, E., and K. J. Meador. 2005. “Adverse Effects of Antiepileptic Drugs.” Acta Neurologica Scandinavica. Supplementum 181 (s181): 30–35. https://doi.org/10.1111/J.1600-0404.2005.00506.X.
Perucca, Emilio, Meir Bialer, and H. Steve White. 2023. “New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System.” CNS Drugs 37 (9): 755–79. https://doi.org/10.1007/S40263-023-01027-2.
Perucca, Emilio, H. Steve White, and Meir Bialer. 2023. “New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development.” CNS Drugs 37 (9): 781–95. https://doi.org/10.1007/S40263-023-01025-4/TABLES/3.
Rajendran, Gayathri, Deepu Bhanu, Baladhandapani Aruchamy, Prasanna Ramani, Nanjan Pandurangan, Kondapa Naidu Bobba, Eun Jung Oh, Ho Yun Chung, Prakash Gangadaran, and Byeong Cheol Ahn. 2022. “Chalcone: A Promising Bioactive Scaffold in Medicinal Chemistry.” Pharmaceuticals 15 (10): 1250. https://doi.org/10.3390/PH15101250.
Richardson, Robert J., Steven Petrou, and Alexander Bryson. 2024. “Established and Emerging GABAA Receptor Pharmacotherapy for Epilepsy.” Frontiers in Pharmacology 15 (February):1341472. https://doi.org/10.3389/FPHAR.2024.1341472/BIBTEX.
Salehi, Bahare, Cristina Quispe, Imane Chamkhi, Nasreddine El Omari, Abdelaali Balahbib, Javad Sharifi-Rad, Abdelhakim Bouyahya, et al. 2021. “Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence.” Frontiers in Pharmacology 11 (January):592654. https://doi.org/10.3389/FPHAR.2020.592654/BIBTEX.
Schmidt, Dieter. 2009a. “Drug Treatment of Epilepsy: Options and Limitations.” Epilepsy & Behavior 15 (1): 56–65. https://doi.org/10.1016/J.YEBEH.2009.02.030.
Schmidt, Dieter, and Steven C. Schachter. 2014. “Drug Treatment of Epilepsy in Adults.” BMJ (Online) 348 (February). https://doi.org/10.1136/BMJ.G254.
Sharma, C S, K S Shekhawat, C S Chauhan, and Neeraj Kumar. 2013. “Synthesis and Anticonvulsant Activity of Some Chalcone Derivatives.” Available Online Www.Jocpr.Com Journal of Chemical and Pharmaceutical Research, no. 5, 450–54. www.jocpr.com.
Shorvon, Simon D. 2011. “The Etiologic Classification of Epilepsy.” Epilepsia 52 (6): 1052–57. https://doi.org/10.1111/J.1528-1167.2011.03041.X.
Sinha, Shweta, Daniela I. Batovska, Bikash Medhi, B. D. Radotra, Ashish Bhalla, Nadezhda Markova, and Rakesh Sehgal. 2019. “In Vitro Anti-Malarial Efficacy of Chalcones: Cytotoxicity Profile, Mechanism of Action and Their Effect on Erythrocytes.” Malaria Journal 18 (1): 1–11. https://doi.org/10.1186/S12936-019-3060-Z/FIGURES/5.
Tomás-Barberán, Francisco A., and Michael N. Clifford. 2000. “Flavanones, Chalcones and Dihydrochalcones - Nature, Occurrence and Dietary Burden.” Journal of the Science of Food and Agriculture. https://doi.org/10.1002/(SICI)1097-0010(20000515)80:7<1073::AID-JSFA568>3.0.CO;2-B.
Treiman, David M. 2001. “GABAergic Mechanisms in Epilepsy.” Epilepsia 42 Suppl 3 (SUPPL. 3): 8–12. https://doi.org/10.1046/J.1528-1157.2001.042SUPPL.3008.X.
Tukur, Abdul Razaq, James Dama Habila, Rachael Gbekele Oluwa Ayo, and Ogunkemi Risikat Agbeke Lyun. 2022a. “Synthesis, Reactions and Pharmacological Applications of Chalcones and Their Derivatives- A Mini Review.” Journal of Chemical Reviews 4 (2): 100–119. https://doi.org/10.22034/JCR.2022.326696.1143.
Valipour, Mehdi. 2022. “Recruitment of Chalcone’s Potential in Drug Discovery of Anti‐SARS‐CoV‐2 Agents.” Phytotherapy Research 36 (12): 4477. https://doi.org/10.1002/PTR.7651.
Verma, S., A. K. Srivastava, and O. P. Pandey. 2018. “A Review on Chalcones Synthesis and Their Biological Activity.” Pharmatutor 6 (2): 22. https://doi.org/10.29161/PT.V6.I2.2018.22.
Waris, Abdul, Muhammad Siraj, Ayyaz Khan, Junyu Lin, Muhammad Asim, and Fahad A. Alhumaydh. 2024. “A Comprehensive Overview of the Current Status and Advancements in Various Treatment Strategies against Epilepsy.” ACS Pharmacology and Translational Science. https://doi.org/10.1021/ACSPTSCI.4C00494/ASSET/IMAGES/LARGE/PT4C00494_0007.JPEG.
Waxman, Stephen G., and Gerald W. Zamponi. 2014. “Regulating Excitability of Peripheral Afferents: Emerging Ion Channel Targets.” Nature Neuroscience 17 (2): 153–63. https://doi.org/10.1038/NN.3602.
Zhuang, Chunlin, Wen Zhang, Chunquan Sheng, Wannian Zhang, Chengguo Xing, and Zhenyuan Miao. 2017a. “Chalcone: A Privileged Structure in Medicinal Chemistry.” Chemical Reviews 117 (12): 7762–7810. https://doi.org/10.1021/acs.chemrev.7b00020.
